The adjustment should take into consideration the control of the patient’s diabetes including both fasting and postprandial glucose levels over the preceding 2–4 weeks, short-acting (prandial insulin or insulin pump, nateglinide and repaglinide) or long-acting (basal insulin, glyburide, glipizide, glimepiride) therapy, the duration of the fasting, and whether the fasting precludes all caloric intake or just carbohydrates. Here, INS is linked to diabetes mellitus.